Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.7.3089

Prognostic Value of Vascular Endothelial Growth Factor Expression in Resected Gastric Cancer  

Liu, Lei (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University)
Ma, Xue-Lei (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University)
Xiao, Zhi-Lan (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University)
Li, Mei (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University)
Cheng, Si-Hang (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University)
Wei, Yu-Quan (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.7, 2012 , pp. 3089-3097 More about this Journal
Abstract
Background and Aims: Vascular endothelial growth factor (VEGF) is a potential prognostic biomarker for patients with resected gastric cancer. However, its role remains controversial. The objective of this study was to conduct a systematic review and meta-analysis of published literature. Methods: Relevant literature was identified using Medline and survival data from published studies were collected following a methodological assessment. Quality assessment of eligible studies and meta-analysis of hazard ratio (HR) were performed to review the correlation of VEGF overexpression with survival and recurrence in patients with gastric cancer. Results: Our meta-analysis included 44 published studies with 4,794 resected patients. VEGF subtype for the prediction of overall survival (OS) included tissue VEGF (HR=2.13, 95% CI 1.71-2.65), circulating VEGF (HR=4.22, 95% CI 2.47-7.18), tissue VEGF-C (HR=2.21, 95% CI 1.58-3.09), tissue VEGF-D (HR=1.73, 95% CI 1.25-2.40). Subgroup analysis showed that HRs of tissue VEGF for OS were, 1.78 (95% CI 0.90-3.51) and 2.31 (95% CI 1.82-2.93) in non-Asians and Asians, respectively. The meta-analysis was also conducted for disease free survival (DFS) and disease specific survival (DSS). Conclusion: Positive expression of tissue VEGF, circulating VEGF, VEGF-C and VEGF-D were all associated with poor prognosis in resected gastric cancer. However, VEGF demonstrated no significant prognostic value for non-Asian populations. Circulating VEGF may be better than tissue VEGF in predicting prognosis.
Keywords
Gastric cancer; prognosis; growth factors and signal transduction; VEGF;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Akdogan R, Aydin F, Ozdemir F, et al (2006). The effects of VEGF and VEGFR-2 on survival in patients with gastric cancer. J Exp Clin Cancer Res, 25, 83-8.
2 Altman DG, Deeks JJ, Higgins JP, Thompson SG (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.   DOI   ScienceOn
3 Altman DG, McShane LM, Sauerbrei W, et al (2006). Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol, 28, 99-105.
4 Amaya H, Matsumura M, Shimomatsuya T, Tanigawa N (1997). Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol, 15, 826-32.
5 Aoyagi K, Kouhuji K, Yano S, et al (2005). VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer, 8, 155-63.   DOI
6 Bai M, Goussia A, Skarlos DV, et al (2007). Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group. Anticancer Res, 27, 2973-83.
7 Bates DO, Hillman NJ, Neal CR, Pocock TM, Williams B (2002). Regulation of microvascular permeability by vascular endothelial growth factors. J Anat, 200, 581-97.   DOI
8 Bazas VM, Demash DV, Galakhin KO, Lukyanova NY, Myasoedov DV (2008). Relation between cell-to-cell adhesion and angiogenesis and clinico-morphological prognostic factors in patients with gastric cancer. Exp Oncol, 30, 235-9.
9 Bray F, Center MM, Jemal A, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
10 Berse B, Brown LF, Van de Water L, et al (1992). Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell, 3, 211-20.   DOI   ScienceOn
11 Burdett S, Ghersi D, Stewart LA, Sydes MR, Tierney JF (2007). Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 16.   DOI   ScienceOn
12 Cao W, Mo M, Wang X, et al (2010). VEGF and cortactin expression are independent predictors of tumor recurrence following curative resection of gastric cancer. J Surg Oncol, 102, 325-30.   DOI
13 Chen J, Li T, Wu Y, et al (2011). Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J Cancer Res Clin Oncol, 137, 1799-812.   DOI
14 Cunha IW, Ioannidis JP, Kyzas PA (2005). Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res, 11, 1434-40.   DOI
15 Chen XC, Gou HF, Zhu J, et al (2011). Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res, 30, 14.   DOI
16 Choi JH, Oh YH, Park YW, et al (2008). Correlation of vascular endothelial growth factor-D expression and VEGFR-3-positive vessel density with lymph node metastasis in gastric carcinoma. J Korean Med Sci, 23, 592-7.   DOI
17 Clark JW, Duda DG, Jain RK, Loeffler JS (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol, 3, 24-40.   DOI
18 Da MX, Wang J, Wu XT, et al (2008). Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res, 39, 92-9.   DOI
19 Deng J, Liang H, Sun D, et al (2009). Vascular endothelial growth factor-D is correlated with hepatic metastasis from gastric cancer after radical gastrectomy. Surgery, 146, 896-905.   DOI
20 Deguchi K, Ichikawa D, Soga K, et al (2010). Clinical significance of vascular endothelial growth factors C and D and chemokine receptor CCR7 in gastric cancer. Anticancer Res, 30, 2361-6.   DOI
21 Deng MH, Dong WG, Qiu WS, Wang TB (2007). Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol, 13, 1794-8.   DOI
22 Detmar M, Wissmann C (2006). Pathways targeting tumor lymphangiogenesis. Clin Cancer Res, 12, 6865-8.   DOI
23 Ding S, Li C, Lin S, et al (2007). Distinct roles of VEGF-A and VEGF-C in tumour metastasis of gastric carcinoma. Oncol Rep, 17, 369-75.
24 Doki Y, Fujiwara Y, Urano N, et al (2006). Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer, 9, 44-9.   DOI
25 Elizalde I, Metges JP, Vidal O, et al (2009). High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg, 96, 1443-51.   DOI
26 Ferrara N, Houck K, Jakeman L, Leung DW (1992). Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev, 13, 18-32.   DOI
27 Endo Y, Fujita H, Yonemura Y, et al (1999). Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res, 5, 1823-9.   DOI   ScienceOn
28 Feldman AL, Paciotti GF, Tamarkin L, et al (2000). Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res, 6, 4628-34.   DOI
29 Ferrara N, Gerber HP, Hillan KJ, Novotny W (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov, 3, 391-400.   DOI   ScienceOn
30 Ferraraccio F, Lieto E, Orditura M, et al (2008). Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol, 15, 69-79.   DOI   ScienceOn
31 Fondevila C, Fuster J, Metges JP, et al (2004). p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer, 90, 206-15.   DOI
32 Fujioka S, Ishibashi Y, Shida A, et al (2005). Prognostic significance of vascular endothelial growth factor D in gastric carcinoma. World J Surg, 29, 1600-7.   DOI
33 Gores GJ, Kurtz DM, Roberts LR, Schoenleber SJ, Talwalkar JA (2009). Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer, 100, 1385-92.   DOI   ScienceOn
34 Fujioka S, Kobayashi K, Shida A, et al (2006). Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma. Int J Clin Oncol, 11, 38-43.   DOI
35 Fujisaki K, Matsuo K, Mitsuyama K, Tanikawa K, Toyonaga A (1998). Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol, 93, 249-52.   DOI
36 Ghaneh P, Neoptolemos JP, Smith RA, Tang J, Tudur-Smith C (2011). Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer, 104, 1440-51.   DOI
37 Han FH, He YL, Li HM, Zhan WH, Zheng DH (2010). The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol, 36, 1172-9.   DOI
38 Hattori N, Kido S, Kitadai Y, et al (2001). Interleukin 8 and vascular endothelial growth factor -- prognostic factors in human gastric carcinomas. Eur J Cancer, 37, 1482-7.   DOI   ScienceOn
39 Hu NZ, Shi H, Xie HJ, Xu JM (2003). Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol, 9, 1421-6.   DOI   ScienceOn
40 Hutton JL, Marson AG, Smith CT, Williamson PR (2002). Aggregate data meta-analysis with time-to-event outcomes. Stat Med, 21, 3337-51.   DOI   ScienceOn
41 Itakura J, Kono K, Takahashi A, et al (2002). Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology, 62, 121-7.   DOI   ScienceOn
42 Ichikura T, Mochizuki H, Ohkura E, Tomimatsu S (2001). Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J Surg Oncol, 78, 132-7.   DOI   ScienceOn
43 Iida S, Kolev Y, Uetake H, et al (2007). Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol, 14, 2738-47.   DOI
44 Ikeguchi M, Oka S, Saito H, et al (1999). The expression of vascular endothelial growth factor and proliferative activity of cancer cells in gastric cancer. Langenbecks Arch Surg, 384, 264-70.   DOI   ScienceOn
45 Joensuu H, Mattson K, Ruotsalainen T, Salven P (1998). High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer, 79, 144-6.   DOI   ScienceOn
46 Jons T, Juttner S, Wissmann C, et al (2006). Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol, 24, 228-40.   DOI
47 Joo SY, Joo YE, Sohn YH, et al (2002). The role of vascular endothelial growth factor (VEGF) and p53 status for angiogenesis in gastric cancer. Korean J Intern Med, 17, 211-9.   과학기술학회마을   DOI   ScienceOn
48 Kakeji Y, Koga T, Sumiyoshi Y, et al (2002). Clinical significance of vascular endothelial growth factor expression in gastric cancer. J Exp Clin Cancer Res, 21, 125-9.   DOI
49 Kang SM, Maeda K, Onoda N, et al (1998). Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology, 55, 594-9.   DOI   ScienceOn
50 Kang SM, Maeda K, Ogawa M, et al (1997). Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma. Int J Cancer, 74, 545-50.   DOI   ScienceOn
51 Kang SM, Maeda K, Onoda N, et al (1999). Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer, 86, 566-71.   DOI   ScienceOn
52 Karayiannakis AJ, Polychronidis A, Syrigos KN, et al (2002). Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg, 236, 37-42.   DOI
53 Kerbel RS (2008). Tumor angiogenesis. N Engl J Med, 358, 2039-49.   DOI   ScienceOn
54 Kim JG, Lee SJ, Sohn SK, et al (2009). No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer. Cancer Res Treat, 41, 218-23.   과학기술학회마을   DOI
55 Kimura H, Konishi K, Nukui T, et al (2001). Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma. J Surg Oncol, 76, 31-6.   DOI   ScienceOn
56 Kitadai Y, Takahashi R, Tanaka S, et al (2003). Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology, 64, 266-74.   DOI
57 Kraft A, Ochs A, Weindel K, et al (1999). Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer, 85, 178-87.   DOI   ScienceOn
58 Kobayashi O, Tsuburaya A, Yoshikawa T, et al (2000). Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett, 153, 7-12.   DOI
59 Kondo A, Saito H, Tsujitani S, et al (1999). Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma. Surgery, 125, 195-201.   DOI
60 Kondo S, Toi M, Yamamoto Y, et al (1996). Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res, 2, 821-6.   DOI
61 Kuwano H, Shimura T, Tsutsumi S, et al (2005). Vascular endothelial growth factor C (VEGF-C) expression in pT2 gastric cancer. Hepatogastroenterology, 52, 629-32.   DOI
62 Lau C, Ng IO, Poon RT, et al (2001). Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg, 233, 227-35.   DOI   ScienceOn
63 Li G, Wu J, Zhou Y, et al (2010). Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumour Biol, 31, 549-58.   DOI
64 Lv XJ, Wang J, Zhan P, et al (2009). Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol, 4, 1094-103.   DOI
65 Parmar MK, Stewart L, Torri V (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.   DOI
66 Ma J, Ru GQ, Zhang L, Zhao ZS (2006). Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World J Gastroenterol, 12, 3970-6.
67 Masselou K, Papastratis G, Tsirlis TD, et al (2008). Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance. World J Gastroenterol, 14, 2691-701.   DOI
68 Park JM, Park KH, Seo HY, et al (2010). Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients. Jpn J Clin Oncol, 40, 1147-53.   DOI
69 Pera M, Soriano-Izquierdo A, Vidal O, et al (2008). Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg, 12, 1005-14.   DOI
70 Wang J, Yang S, Zhang H, et al (2011). Aurora-A as an independent molecular prognostic marker in gastric cancer. Oncol Rep, 26, 23-32.
71 Yang Q, Ye ZY, Zhang JX, et al (2010). Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Anat Rec (Hoboken), 293, 2012-9.   DOI
72 Han FH, He YL, Li HM, Zhan WH, Zheng DH (2010). The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol, 36, 1172-9.   DOI   ScienceOn
73 Chen XC, Gou HF, Zhu J, et al (2011). Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res, 30, 14.   DOI
74 Deguchi K, Ichikawa D, Soga K, et al (2010). Clinical significance of vascular endothelial growth factors C and D and chemokine receptor CCR7 in gastric cancer. Anticancer Res, 30, 2361-6.
75 Detmar M, Wissmann C (2006). Pathways targeting tumor lymphangiogenesis. Clin Cancer Res, 12, 6865-8.   DOI
76 Ding S, Li C, Lin S, et al (2007). Distinct roles of VEGF-A and VEGF-C in tumour metastasis of gastric carcinoma. Oncol Rep, 17, 369-75.
77 Ghaneh P, Neoptolemos JP, Smith RA, Tang J, Tudur-Smith C (2011). Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer, 104, 1440-51.   DOI   ScienceOn
78 Kim JG, Lee SJ, Sohn SK, et al (2009). No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer. Cancer Res Treat, 41, 218-23.   DOI   ScienceOn